Why relentless innovation is Pro Medicus’ biggest opportunity and risk

Описание: Few companies have captured the attention of the market quite like Pro Medicus in recent years. It has been the poster child of growth stocks.

The share price has reflected that growth, surging from just above $4 in 2017 to a high above $111 before yesterday’s sharp selloff despite record results.

After such incredible growth, one might expect co-founder and CEO, Dr Sam Hupert, to be taking a step back and enjoying some of the spoils – but that’s far from the case.

“This is the best time to be in the industry that I can remember”, says Hupert with a smile on his face and a fire in his eyes.
Hupert remains a clinician at heart and speaks passionately about “moving the needle clinically” and having a positive impact on “tens of millions” of patients.

Add to the mix the development of artificial intelligence, which Hupert believes perfectly complements healthcare imaging and has the potential to raise the bar again, and you begin to understand what is driving both the man and the business.

In the following interview, Hupert talks through the major contract wins from the last six months and the forward pipeline, shares how the company positions itself with thought leaders and luminaries to expand the opportunity set, and provides insights into how Pro Medicus plans to stay ahead of its competition.

Note: This interview was recorded on February 15, 2024.